ASX healthcare stocks generating investors’ interest

The next wave of healthcare innovation is taking shape and these companies are leading it, turning medical breakthroughs into treatments that add value to customer’s lives.

Mesoblast Limited (ASX: MSB) 

keeps moving ahead as a big player in the field of allogeneic cell medicines. Its progress is mainly because of the strong rollout of Ryoncil, which became the first FDA approved mesenchymal stromal cell (MSC) therapy in the world.

For the September 2025 quarter, Mesoblast made around US$20.6 million in product revenue which is 69% higher compared to the last quarter. 

Cash on hand was about US$145 million, helped by a new US$50 million convertible note deal, giving the company more flexibility to fund future growth.

Looking forward, Mesoblast wants to expand Ryoncil and also push ahead its Revascor for heart failure and Rexlemestrocel-L for back pain trials. With these plans, the company is putting itself at the front in the next wave of advanced cell therapies for big global markets.

Orthocell Limited (ASX: OCC) 

is showing strong growth in the regenerative medicine field, led by its main product Remplir and its growing presence globally. 

In the September 2025 quarter, it made a record revenue of around $3.0 million which is 11% higher than the June quarter and 50% up compared to last year. 

The company’s cash balance stayed healthy at $27 million which keeps it in a good spot for more international expansion.

In October, Orthocell increased its holding in Marine Biomedical from 1.7% to 12% by investing $1.0 million and this deal also gave them exclusive worldwide rights for PearlBone which is a new type of bone regeneration material.

With rising sales, a wider distributor base and new innovations coming up, Orthocell is fast moving towards becoming a key player in regenerative medicine.

Mayne Pharma Group Limited (ASX: MYX) 

showed impressive progress in FY25, driven by good execution in Women’s Health and Dermatology and also its planned buyout by Cosette Pharmaceuticals. The deal is valued at around $672 million and now waiting for FIRB clearance which is expected by 31 October 2025.
The company reported $408.1 million in revenue which is 5% higher than last year. Its gross profit increased 13% to $247.3 million and EBITDA more than doubled to $47 million.
The company also managed to cut down its net loss to $90.1 million, which is an improvement of $78.5 million compared to FY24. It also generated $45.4 million in operating cash flow. The main push came from the Women’s Health segment where NEXTSTELLIS sales jumped 41%.
Going forward, Mayne aims to expand more in the U.S. market, boost its Women’s Health products and improve profits through smart and cost-efficient growth in Dermatology and International business.

(Source: Company Announcements)